Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Ketamine in Treatment-Resistant Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients, 21-65 years;~2. Women of childbearing potential must agree to use a medically accepted means of contraception for the duration of the study;~3. Primary diagnosis of major depressive disorder as assessed by the SCID-P;~4. Current depressive episode;~5. History of a failure to respond to at least one (1) adequate pharmacotherapy trials in the current major depressive episode;~6. Subjects must have scored ≥ 30 on the IDS-C30 at Screening ≥ 24 at Treatment Day #1 and #2;~7. Each subject must have a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign an informed consent document;~8. Subjects must be able to identify a family member, physician, or friend who will participate in the Treatment Contract and serve as an emergency contact.~Exclusion Criteria:~1. Women who plan to become pregnant, are pregnant or are breast-feeding;~2. Any unstable medical illness including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease;~3. Clinically significant abnormal findings of laboratory parameters, physical examination, or ECG;~4. Lifetime history of schizophrenia, schizoaffective disorder, bipolar disorder, OCD, mental retardation, pervasive developmental disorders, or Tourette's syndrome;~5. Drug or alcohol abuse or dependence within the preceding 6 months;~6. Lifetime abuse or dependence on ketamine or phencyclidine;~7. Patients judged by study investigator to be at high risk for suicide.~8. Previous participation in a ketamine study at Mount Sinai

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Subjects randomized to this arm will receive the active study medication, intranasal ketamine.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects randomized to this arm will receive intranasal saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).